

Osteonecrosis - Pipeline Insight, 2021

<https://marketpublishers.com/r/O18E83C5DC44EN.html>

Date: October 2021

Pages: 60

Price: US\$ 1,500.00 (Single User License)

ID: O18E83C5DC44EN

Abstracts

This report can be delivered to the clients within 24 hours

DelveInsight's, "Osteonecrosis – Pipeline Insight, 2021," report provides comprehensive insights about 4+ companies and 4+ pipeline drugs in Osteonecrosis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

Osteonecrosis Understanding

Osteonecrosis: Overview

Osteonecrosis, also known as avascular necrosis (AVN), aseptic necrosis or ischemic bone necrosis, is a disease resulting in the death of bone cells. If the process involves the bones near a joint, it often leads to collapse of the joint surface and subsequent arthritis due to an irregular joint surface. The exact cause is unknown. Although it can happen in any bone, osteonecrosis most commonly affects the ends (epiphysis) of long bones such as the femur (thigh bone). Commonly involved bones are the upper femur (ball part of the hip socket) the lower femur (a part of the knee joint), the upper humerus (upper arm bone involving the shoulder joint), and the bones of ankle joint. The disease may affect just one bone, more than one bone at the same time, or more than one bone at different times. Orthopedic surgeons most often diagnose the disease using either an

X-ray of magnetic resonance scan (MRI). Appropriate treatment for osteonecrosis is necessary to keep joints from collapsing. If untreated, most patients will experience severe pain and limitation in movement within two years. There is no agreed upon optimal treatment for individuals with osteonecrosis. Early intervention is essential to preserve the joints, but most people are diagnosed late in the disease process.

'Osteonecrosis - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Osteonecrosis pipeline landscape is provided which includes the disease overview and Osteonecrosis treatment guidelines. The assessment part of the report embraces, in depth Osteonecrosis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Osteonecrosis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Osteonecrosis R&D. The therapies under development are focused on novel approaches to treat/improve Osteonecrosis.

Osteonecrosis Emerging Drugs Chapters

This segment of the Osteonecrosis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Osteonecrosis Emerging Drugs

Autologous cultured chondrocytes: Vericel

MACI® (autologous cultured chondrocytes on porcine collagen membrane) is an autologous cellular scaffold product that is indicated for the repair of symptomatic single or multiple full-thickness cartilage defects of the knee with or without bone involvement

in adults. The MACI implant consists of autologous cultured chondrocytes seeded onto a resorbable Type I/III collagen membrane. Autologous cultured chondrocytes are human-derived cells which are obtained from the patient's own cartilage for the manufacture of MACI. This cell therapy is currently being evaluated in Phase II stage of development for the treatment of Osteonecrosis.

Further product details are provided in the report.....

Osteonecrosis: Therapeutic Assessment

This segment of the report provides insights about the different Osteonecrosis drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Osteonecrosis

There are approx. 4+ key companies which are developing the therapies for Osteonecrosis. The companies which have their Osteonecrosis drug candidates in the most advanced stage, i.e. Phase II include, Vericel. Phases

DelveInsight's report covers around 4+ products under different phases of clinical development like

Late stage products (Phase III)

Mid-stage products (Phase II)

Early-stage product (Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Osteonecrosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral

Parenteral

Intravenous

Subcutaneous

Topical.

Molecule Type

Products have been categorized under various Molecule types such as

Monoclonal Antibody

Peptides

Polymer

Small molecule

Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Osteonecrosis: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Osteonecrosis therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Osteonecrosis drugs.

Osteonecrosis Report Insights

Osteonecrosis Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

Osteonecrosis Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

How many companies are developing Osteonecrosis drugs?

How many Osteonecrosis drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Osteonecrosis?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Osteonecrosis therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Osteonecrosis and their status?

What are the key designations that have been granted to the emerging drugs?

Contents

Introduction

Executive Summary

Osteonecrosis: Overview

Causes

Mechanism of Action

Signs and Symptoms

Diagnosis

Disease Management

Pipeline Therapeutics

Comparative Analysis

Therapeutic Assessment

Assessment by Product Type

Assessment by Stage and Product Type

Assessment by Route of Administration

Assessment by Stage and Route of Administration

Assessment by Molecule Type

Assessment by Stage and Molecule Type

Late Stage Products (Phase III)

Comparative Analysis

Tegoprazan: HK inno.N Corporation

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report

Mid Stage Products (Phase II)

Comparative Analysis

Autologous cultured chondrocytes: Vericel

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report

Preclinical stage products

Comparative Analysis

Research program: small molecule and peptide therapeutics: Enzo Biochem

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report

Inactive Products

Comparative Analysis

Osteonecrosis Key Companies

Osteonecrosis Key Products

Osteonecrosis- Unmet Needs

Osteonecrosis- Market Drivers and Barriers

Osteonecrosis- Future Perspectives and Conclusion

Osteonecrosis Analyst Views

Osteonecrosis Key Companies

Appendix

List Of Tables

LIST OF TABLES

- Table 1 Total Products for Osteonecrosis
- Table 2 Late Stage Products
- Table 3 Mid Stage Products
- Table 4 Early Stage Products
- Table 5 Pre-clinical & Discovery Stage Products
- Table 6 Assessment by Product Type
- Table 7 Assessment by Stage and Product Type
- Table 8 Assessment by Route of Administration
- Table 9 Assessment by Stage and Route of Administration
- Table 10 Assessment by Molecule Type
- Table 11 Assessment by Stage and Molecule Type
- Table 12 Inactive Products

List Of Figures

LIST OF FIGURES

- Figure 1 Total Products for Osteonecrosis
- Figure 2 Late Stage Products
- Figure 3 Mid Stage Products
- Figure 4 Early Stage Products
- Figure 5 Preclinical and Discovery Stage Products
- Figure 6 Assessment by Product Type
- Figure 7 Assessment by Stage and Product Type
- Figure 8 Assessment by Route of Administration
- Figure 9 Assessment by Stage and Route of Administration
- Figure 10 Assessment by Molecule Type
- Figure 11 Assessment by Stage and Molecule Type
- Figure 12 Inactive Products

I would like to order

Product name: Osteonecrosis - Pipeline Insight, 2021

Product link: <https://marketpublishers.com/r/O18E83C5DC44EN.html>

Price: US\$ 1,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/O18E83C5DC44EN.html>